Eli Lilly announced that its new oral medication for the acute treatment of migraines is now available for prescription and will be available in pharmacies in the next few days.
The drugmaker's first 2020 launch, Reyvow, is a new class of acute treatment for migraines — the first and only FDA-approved ditan, a 5-HT1F receptor agonist, believed to act both centrally and peripherally.
Reyvow was approved in October 2019 based on results where 28-39% of patients achieved fast and complete elimination of migraine pain at two hours versus 15% and 21% with placebo across two clinical studies and three doses.
The new treatment will go up against Allergan’s Ubrelvy, another drug that treats migraines as they happen, which won approval in late 2019 and is now available on the market.
Read the press release
